Bristol Myers Trades at a Fraction of Lilly's Price Tag

Bristol Myers Squibb (BMY) closed at 62.86, down 1.60% on Sept. 29, 2026, while Eli Lilly (LLY) finished at 1184.63, essentially flat at -0.01%, as investors weigh Bristol's cash generation and cheaper valuation against Lilly's faster growth.

Two of the largest names in American pharmaceuticals ended Tuesday's session pointing in opposite directions, and not just on the tape. Bristol Myers Squibb (BMY) last traded at 62.86, down 1.60% from the prior close of 63.88, with a session range of 61.95 to 63.89. Eli Lilly (LLY) finished essentially unchanged at 1184.63, a move of -0.01% against the previous close of 1184.78, after swinging between 1168.47 and 1192.94. Those are the last trades recorded as of 20:00 GMT on Sept. 29, 2026; the market is closed.

The gap in the headline numbers is the easy part. Lilly's share price is roughly 18.8 times Bristol's — an illustrative ratio drawn straight from the two closing quotes, not a valuation measure in itself, since share prices reflect how many shares each company has outstanding as much as what each business is worth. The harder question, and the one Motley Fool put to readers this week, is which of the two is the better buy in 2026 when one trades at a fraction of the other's valuation while throwing off substantial free cash flow, and the other offers explosive growth with a price to match.

The cash-flow case and what it is paying for

Bristol Myers Squibb's appeal is the plainest kind there is in large-cap pharma: a business that converts revenue into free cash flow — the money left after operating costs and capital spending — and a share price that does not demand much in the way of future surprises. When a drugmaker's multiple sits well below the sector's fastest grower, the market is usually telling you something specific rather than something vague. In Bristol's case, the concern named in the comparison is concentration risk: too much of the revenue base resting on too few products.

That matters because pharmaceutical concentration has a scheduled end date. Patents expire, generics arrive, and revenue that looked durable for years can compress inside a handful of quarters. Investors who buy the cash flow are implicitly betting that either the pipeline replaces what rolls off, or that management redeploys the cash — into buybacks, dividends or acquisitions — fast enough to keep per-share economics intact. Neither outcome is automatic, and the discount in the share price exists precisely because the market is not willing to assume it.

Tuesday's session did Bristol no favors in the short term. Its 1.60% decline was steeper than the broad market: the S&P 500, proxied by SPY, closed at $764.20, off 0.18% on the day. The Dow 30 proxy DIA ended at $512.88, down 0.22%, while the Nasdaq 100 proxy QQQ finished at $737.93, up 0.19%. Bristol underperformed all three.

Growth at 1184.63, and the arithmetic of expectations

Eli Lilly is the mirror image. A stock that carries a premium valuation is a stock whose owners have already paid for several years of growth in advance. The return from here depends less on whether the company grows and more on whether it grows as fast as the price implies. That is a different risk from Bristol's — not a cliff, but a treadmill. Miss a quarter, see a competitor's data read out better than expected, or run into manufacturing or reimbursement friction, and a high multiple contracts quickly.

Lilly's flat close is itself informative. A move of -0.01% on a day when the intraday range spanned more than 24 points of price action suggests plenty of two-way traffic and no directional conviction by the bell. Stocks priced for acceleration tend to trade that way: wide ranges, narrow net changes, until the next catalyst arrives.

Two different bets, not two versions of the same one

Framing this as "cheap versus expensive" flattens the decision. The two stocks are exposed to different things going wrong.

• Bristol Myers Squibb: the downside scenario is a revenue base that shrinks faster than replacements ramp. The upside is that the cash flow keeps arriving while the market pays a low multiple for it, and any pipeline success is close to free optionality.
• Eli Lilly: the downside scenario is multiple compression — the business performs, the stock does not. The upside is that high-growth franchises compound for longer than skeptics expect, which is historically how the largest pharma winners have been made.

An income-oriented investor and a growth investor should reach different answers, and both can be right. What neither should do is buy the valuation gap on its own. A low multiple is not a margin of safety when the earnings behind it have a known expiry; a high multiple is not proof of quality when the growth is already discounted.

What to watch from here

Three things will settle this comparison over the coming year, and none of them is the current share price. First, Bristol's pipeline disclosures and any capital allocation moves that signal how management intends to bridge its concentration exposure. Second, clinical and commercial updates from Lilly's growth franchises, where the bar is set by expectations rather than by last year's results. Third, the rate environment and sector rotation: defensive cash generators and premium growth names do not respond to the same macro inputs, and a market that has been rewarding one has a habit of switching without notice.

For now the scoreboard is simple and provisional. Bristol closed at 62.86 after a down day that ran worse than the index. Lilly closed at 1184.63, unmoved. Anyone treating that as a verdict is reading a single session as a thesis.

Key facts

• BMY last close: 62.86, -1.60% (as of 20:00 GMT, Sept. 29, 2026)
• LLY last close: 1184.63, -0.01% (as of 20:00 GMT, Sept. 29, 2026)
• Bristol's day range: 61.95–63.89, vs. prior close of 63.88
• Benchmark: S&P 500 proxy SPY closed at $764.20, -0.18%

Frequently asked questions

How did Bristol Myers Squibb and Eli Lilly close on Sept. 29, 2026?

Bristol Myers Squibb last traded at 62.86, down 1.60% from a prior close of 63.88, with a session range of 61.95 to 63.89. Eli Lilly closed at 1184.63, a change of -0.01% against its prior close of 1184.78, after trading between 1168.47 and 1192.94. Both figures are as of 20:00 GMT.

Why is Bristol Myers Squibb valued at a fraction of Eli Lilly?

The market is pricing two different profiles. Bristol generates substantial free cash flow but carries concentration risk, meaning a large share of revenue depends on a limited number of products that will eventually face patent expiry. Eli Lilly is priced for explosive growth. A discount reflects uncertainty about revenue durability, not necessarily poor business quality.

What is concentration risk in a pharmaceutical company?

Concentration risk means a disproportionate share of sales comes from a small number of drugs. When those products lose patent protection, generic competition can compress revenue sharply within a few quarters. The company must replace that income through its pipeline, acquisitions, or by returning cash to shareholders fast enough to protect per-share earnings.

What is free cash flow and why does it matter here?

Free cash flow is the cash a business has left after operating expenses and capital spending. It funds dividends, buybacks and acquisitions without new borrowing. For a drugmaker facing patent expiries, strong free cash flow is what gives management the ability to buy or build replacement revenue before the existing base declines.

Did either stock outperform the market that day?

No. Bristol Myers Squibb fell 1.60%, worse than all three major benchmarks. The S&P 500 proxy SPY closed at $764.20, down 0.18%, the Dow 30 proxy DIA at $512.88, down 0.22%, and the Nasdaq 100 proxy QQQ at $737.93, up 0.19%. Eli Lilly was essentially flat at -0.01%.

Does a higher share price mean Eli Lilly is more expensive than Bristol Myers?

Not by itself. Share price depends on how many shares a company has issued, so a 1184.63 quote is not inherently pricier than a 62.86 quote. Valuation is measured against earnings, cash flow or sales. The lead comparison holds that Bristol trades at a fraction of Lilly's valuation on those underlying measures.

Sources

• Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool

Photo: Pexels · Pixabay Content License — source